Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages

G. J. Melendez-Torres; Xavier Armoiry; Rachel Court; Jacoby Patterson; Alan Kan; Peter Auguste; Jason Madan; Carl Counsell; Olga Ciccarelli; Aileen Clarke

doi:10.1186/s12883-018-1162-9

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages

G. J. Melendez-Torres (Corresponding Author), Xavier Armoiry, Rachel Court, Jacoby Patterson, Alan Kan, Peter Auguste, Jason Madan, Carl Counsell, Olga Ciccarelli, Aileen Clarke

Research output: Contribution to journal › Article

4 Citations (Scopus)

4 Downloads (Pure)

Abstract

We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.

Original language	English
Article number	162
Journal	BMC Neurology
Volume	18
DOIs	https://doi.org/10.1186/s12883-018-1162-9
Publication status	Published - 3 Oct 2018

Fingerprint

Keywords

multiple sclerosis
clinically isolated syndrome
beta-interferon
glatiramer acetate
systematic review
economic evaluation

Cite this

Melendez-Torres, G. J., Armoiry, X., Court, R., Patterson, J., Kan, A., Auguste, P., ... Clarke, A. (2018). Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages. BMC Neurology, 18, [162]. https://doi.org/10.1186/s12883-018-1162-9

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis : systematic review and network meta-analysis of trials including recommended dosages. / Melendez-Torres, G. J. (Corresponding Author); Armoiry, Xavier; Court, Rachel; Patterson, Jacoby; Kan, Alan; Auguste, Peter; Madan, Jason; Counsell, Carl; Ciccarelli, Olga; Clarke, Aileen.

In: BMC Neurology, Vol. 18, 162, 03.10.2018.

Research output: Contribution to journal › Article

Melendez-Torres, GJ, Armoiry, X, Court, R, Patterson, J, Kan, A, Auguste, P, Madan, J, Counsell, C, Ciccarelli, O & Clarke, A 2018, 'Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages', BMC Neurology, vol. 18, 162. https://doi.org/10.1186/s12883-018-1162-9

Melendez-Torres, G. J. ; Armoiry, Xavier ; Court, Rachel ; Patterson, Jacoby ; Kan, Alan ; Auguste, Peter ; Madan, Jason ; Counsell, Carl ; Ciccarelli, Olga ; Clarke, Aileen. / Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis : systematic review and network meta-analysis of trials including recommended dosages. In: BMC Neurology. 2018 ; Vol. 18.

@article{1e0986b2175c49bd9576cb55fb84357c,

title = "Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages",

abstract = "We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.",

keywords = "multiple sclerosis, clinically isolated syndrome, beta-interferon, glatiramer acetate, systematic review, economic evaluation",

author = "Melendez-Torres, {G. J.} and Xavier Armoiry and Rachel Court and Jacoby Patterson and Alan Kan and Peter Auguste and Jason Madan and Carl Counsell and Olga Ciccarelli and Aileen Clarke",

note = "This work is part of a larger report commissioned by the NIHR HTA Programme as project number ID809. Aileen Clarke and G.J. Melendez-Torres are partly supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University Hospitals Birmingham NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, NICE or the Department of Health and Social Care.",

year = "2018",

month = "10",

day = "3",

doi = "10.1186/s12883-018-1162-9",

language = "English",

volume = "18",

journal = "BMC Neurology",

issn = "1471-2377",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis

T2 - systematic review and network meta-analysis of trials including recommended dosages

AU - Melendez-Torres, G. J.

AU - Armoiry, Xavier

AU - Court, Rachel

AU - Patterson, Jacoby

AU - Kan, Alan

AU - Auguste, Peter

AU - Madan, Jason

AU - Counsell, Carl

AU - Ciccarelli, Olga

AU - Clarke, Aileen

N1 - This work is part of a larger report commissioned by the NIHR HTA Programme as project number ID809. Aileen Clarke and G.J. Melendez-Torres are partly supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University Hospitals Birmingham NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, NICE or the Department of Health and Social Care.

PY - 2018/10/3

Y1 - 2018/10/3

N2 - We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.

AB - We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.

KW - multiple sclerosis

KW - clinically isolated syndrome

KW - beta-interferon

KW - glatiramer acetate

KW - systematic review

KW - economic evaluation

U2 - 10.1186/s12883-018-1162-9

DO - 10.1186/s12883-018-1162-9

M3 - Article

VL - 18

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

M1 - 162

ER -

Access to Document

10.1186/s12883-018-1162-9Licence: CC BY

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Final published version, 844 KBLicence: CC BY